![Kanad D. Das](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Kanad D. Das
Director/Board Member at
Oncomyx Therapeutics, Inc.
Profile
Kanad D.
Das has worked as an Investment Director at Boehringer Ingelheim (Venture Capital) since 2018.
He also currently holds Director positions at Actym Therapeutics, Inc. and Oncomyx Therapeutics, Inc.
Kanad D. Das active positions
| Companies | Position | Start |
|---|---|---|
Oncomyx Therapeutics, Inc.
 Oncomyx Therapeutics, Inc. Packaged SoftwareTechnology Services Develops and operates software platform to orchestrate an immune response & treat cancer | Director/Board Member | - |
Actym Therapeutics, Inc.
 Actym Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops immune-oncology therapies | Director/Board Member | - |
Boehringer Ingelheim (Venture Capital)
 Boehringer Ingelheim (Venture Capital) Investment ManagersFinance BIVF invests in companies located across the globe including the United States, Europe and China. The firm targets companies operating in groundbreaking innovation including cancer, regenerative medicine, auto-immunity indications, digital solutions and infectious disease. It participaotes in seed and early stage capital requirements. The firm acquires minority interest and makes follow-on investments. It also takes seat on the board of directors. | Private Equity Investor | 01/05/2018 |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
6
1st degree connections
3
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 3 |
|---|---|
Boehringer Ingelheim (Venture Capital)
Boehringer Ingelheim (Venture Capital) Investment ManagersFinance BIVF invests in companies located across the globe including the United States, Europe and China. The firm targets companies operating in groundbreaking innovation including cancer, regenerative medicine, auto-immunity indications, digital solutions and infectious disease. It participaotes in seed and early stage capital requirements. The firm acquires minority interest and makes follow-on investments. It also takes seat on the board of directors. | Finance |
Actym Therapeutics, Inc.
Actym Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops immune-oncology therapies | Health Technology |
Oncomyx Therapeutics, Inc.
Oncomyx Therapeutics, Inc. Packaged SoftwareTechnology Services Develops and operates software platform to orchestrate an immune response & treat cancer | Technology Services |
- Stock Market
- Insiders
- Kanad D. Das
